Recent interventions in treating bacterial meningitis

Paper Details

Research Paper 10/08/2022
Views (439) Download (41)

Recent interventions in treating bacterial meningitis

Syeda Ayesha Ali, Muhammad Kamran Taj, Safa Farooqi, Saima Azam, Ashiq Hussain, Syeda Hafsa Ali, Zaib-Un-Nisa Hanif
Int. J. Biosci.21( 2), 212-229, August 2022.
Certificate: IJB 2022 [Generate Certificate]


Bacterial meningitis (BM) affects the central nervous system (CNS) and is a significant long-term sequela for 50% of survivors globally. Resource-poor areas have a higher prevalence of acute bacterial meningitis than resource-rich ones. The pathogenesis of BM involves intricate pathways linked to bacterial survival and proliferation in the circulation, increased blood-brain barrier (BBB) permeability, oxidative stress, and an overactive inflammatory response in the central nervous system (CNS). Drug-resistant bacteria make treating meningitis more challenging, as the morbidity rate for BM is still very high. There has been promising progress in neurology recently for drug supplements that effectively prevent and treat BM. There have been hopeful advancements in neurology recently for medication supplements that effectively prevent and cure BM. Numerous in vivo and in vitro researches have gone into detail on how drugs affect BM and its important mechanism. However, prevention of BM at community and individual levels is vital and can be achieved via various strategies. Some of the strategies are particular hygiene protocols, isolation, social distancing, quite smoking, immunoglobulin treatments and many other methods. Yet, vaccinations still remain the best stratagem against the risk of bacterial meningitis and several other severe infections at the level of the community.


Adriani KS, Brouwer MC, Van der Ende A,  Van de Beek D. 2013. Bacterial meningitis in adults after splenectomy and hyposplenic states. Paper presented at the Mayo Clinic proceedings.

Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME. 2019. Primary immunodeficiency and autoimmunity: a comprehensive review. Journal of autoimmunity 99, 52-72.

Andes DR, Craig WA. 1999. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infectious disease clinics of North America 13(3), 595-618.

Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. 201. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. Southern medical journal 104(1), 40-45.

Balmer P, Burman C, Serra L, York LJ. 2018. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Human vaccines and immunotherapeutics 14(5), 1118-1130.

Barnhill AE, Brewer MT, Carlson SA. 2012. Adverse Effects of Antimicrobials via Predictable or Idiosyncratic Inhibition of Host Mitochondrial Components. Antimicrobial agents and chemotherapy 56(8), 4046-4051.

Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. 2017. The pathogenesis of Ebola virus disease. Annual Review of Pathology: Mechanisms of Disease 12, 387-418.

Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Siber G. 2000. efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. The Pediatric infectious disease journal 19(3), 187-195.

Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, Verheij TJ. 2015. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. New England Journal of Medicine 372(12), 1114-1125.

Bradley JS. 2002. Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. The Pediatric infectious disease journal 21(6), 592-598.

Brouwer MC, Tunkel AR, Van de Beek D. 2010. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clinical microbiology reviews 23(3), 467-492.

Campbell H, Borrow R, Salisbury D, Miller E. 2009. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine, 27, B20-B29.

Capeding MRZ, Nohynek H, Käyhty H, Pascual LG, Sunico ES, Tamundong AA, Ruutu P. 1998. Antibody responses of three Haemophilus influenzae type b conjugate vaccines after one, two and three doses in Filipino children. Vaccine 16(9-10), 1004-1008.

Capone A, Giannella M, Fortini D, Giordano, A, Meledandri M, Ballardini M, Petrosillo N. 2013. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clinical Microbiology and Infection 19(1), E23-E30.

Chandran A, Watt JP, Santosham M. 2005. Prevention of Haemophilus influenzae type b disease: past success and future challenges. Expert review of vaccines 4(6), 819-827.

Chinen J, Shearer WT. 2010. Secondary immunodeficiencies, including HIV infection. Journal of Allergy and Clinical Immunology 125(2), S195-S203.

Costerus JM, Brouwer MC, Bijlsma MW, and van de Beek D. 2017. Community-acquired bacterial meningitis. Current Opinion in Infectious Diseases 30(1), 135-141.

Coulehan JL, Michaels RH, Hallowell C, Schults R, Welty TK, Kuo J. 1984. Epidemiology of Haemophilus influenzae type B disease among Navajo Indians. Public health reports 99(4), 404.

Cuevas L, Hart C. 1993. Chemoprophylaxis of bacterial meningitis. Journal of Antimicrobial Chemotherapy 31(suppl_B), 79-91.

Cutts F, Zaman S, Enwere Gy, Jaffar S, Levine O, Okoko J, Leach A. 2005. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. The lancet 365(9465), 1139-1146.

Daudia A, Biswas D, Jones NS. 2007. Risk of meningitis with cerebrospinal fluid rhinorrhea. Annals of Otology, Rhinology and Laryngology, 116(12), 902-905.

Daugla D, Gami J, Gamougam K, Naibei N, Mbainadji L, Narbé M, Coldiron M. 2014. Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. The lancet 383(9911), 40-47.

DeLeo FR, Otto M, Kreiswirth BN, Chambers, 2010. Community-associated meticillin-resistant Staphylococcus aureus. The Lancet, 375(9725), 1557-1568.

Doherty M, Buchy P, Standaert B, Giaquinto, C, Prado-Cohrs D. 2016. Vaccine impact: Benefits for human health. Vaccine 34(52), 6707-6714.

Duke T, Michael A, Mokela D, Wal T, Reeder J. 2003. Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries? Archives of Disease in Childhood 88(6), 536-539.

Egermann U, Stanga Z, Ramin A, Acosta F, Stucki A, Gerber P, Cottagnoud P. 2009. Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. Antimicrobial agents and chemotherapy 53(7), 3030-3033.

Englhard AS, Volgger V, Leunig A, Meßmer C. S, Ledderose GJ. 2018. Spontaneous nasal cerebrospinal fluid leaks: management of 24 patients over 11 years. European Archives of Oto-rhino-laryngology 275(10), 2487-2494.

Erdem H, Elaldi N, Öztoprak N, Sengoz G, AKO, Kaya S, Pekok AU. 2014. Mortality indicators in pneumococcal meningitis: therapeutic implications. International Journal of Infectious Diseases 19, 13-19.

Eskola J, Käyhty H, Takala AK, Peltola H, Rönnberg PR, Kela E, Mäkelä PH. 1990. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. New England Journal of Medicine, 323(20), 1381-1387.

Fraser A, Gafter-Gvili A, Paul M, Leibovici L. 2005. Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials. European Journal of Clinical Microbiology and Infectious Diseases, 24(3), 172-181.

Galimand M, Gerbaud G, Guibourdenche M, Riou JY, Courvalin P. 1998. High-level chloramphenicol resistance in Neisseria meningitidis. New England Journal of Medicine 339(13), 868-874.

Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. 2009. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. International journal of epidemiology 38(2), 413-418.

Goldacre M, Wotton C, Maisonneuve J. 2014. Maternal and perinatal factors associated with subsequent meningococcal, Haemophilus or enteroviral meningitis in children: database study. Epidemiology and Infection 142(2), 371-378.

Grief SN. 2013. Upper respiratory infections. Primary Care: Clinics in Office Practice 40(3), 757-770.

Gupta N, Limbago BM, Patel JB, Kallen AJ. 2011. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clinical infectious diseases 53(1), 60-67.

Gupta S, Govil, D, Kakar PN, Prakash O, Arora D, Das S, Malhotra A. 2009. Colistin and polymyxin B: a re-emergence. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 13(2), 49-53.

Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, Sáfadi MA. 2012. The changing and dynamic epidemiology of meningococcal disease. Vaccine 30, B26-B36.

Hargreaves RM, Slack MP, Howard AJ, Anderson E, Ramsay ME. 1996. Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. bmj, 312(7024), 160-161

Hasbun R. 2019. Update and advances in community acquired bacterial meningitis. Current Opinion in Infectious Diseases 32(3), 233-238.

Jiménez-Mejías M, Pichardo-Guerrero C, Márquez-Rivas F, Martín-Lozano D, Prados T, Pachón J. 2002. Cerebrospinal Fluid Penetration and Pharmacokinetic/Pharmacodynamic Parameters of Intravenously Administered Colistin in a Case of Multidrug-Resistant Acinetobacter baumannii Meningitis. European Journal of Clinical Microbiology and Infectious Diseases 21(3), 212-214.

Kaaijk P, Van der Ende A, Berbers G, Van den Dobbelsteen GP, Rots NY. 2012. Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands. BMC Infectious Diseases 12(1), 1-6.

Käyhty H, Lockhart S, Schuerman L. 2008. Immunogenicity and reactogenicity of pneumococcal conjugate vaccines in infants and children. Pneumococcal Vaccines: The Impact of Conjugate Vaccines 227-243.

Kelly DF, Moxon ER, Pollard AJ. 2004. Haemophilus influenzae type b conjugate vaccines. Immunology 113(2), 163-174.

Khatami A, Pollard AJ. 2010. The epidemiology of meningococcal disease and the impact of vaccines. Expert review of vaccines 9(3), 285-298.

Kim BN, Peleg A Y, Lodise TP, Lipman J, Li J, Nation R, Paterson DL. 2009. Management of meningitis due to antibiotic-resistant Acinetobacter species. The Lancet infectious diseases 9(4), 245-255.

Kim SH, Chung DR, Song JH, Baek JY, Thamlikitkul V, Wang H, Tan SH. 2020. Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: emergence of drug-resistant non-vaccine serotypes. Vaccine 38(38), 6065-6073.

Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. New England Journal of Medicine 349(14), 1341-1348.

Klugman KP, Walsh AL, Phiri A, Molyneux, E. M. 2008. Mortality in penicillin-resistant pneumococcal meningitis. The Pediatric infectious disease journal 27(7), 671-672.

Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. 2015. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 64(34), 944-947.

Ladhani SN, Ramsay M, Borrow R, Riordan A, Watson JM, Pollard AJ. 2016. Enter B and W: two new meningococcal vaccine programmes launched. Archives of disease in childhood 101(1), 91-95.

Le J, Bookstaver PB, Rudisill CN, Hashem M. G, Iqbal R, James CL, Sakoulas G. 2010. Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy. Annals of Pharmacotherapy 44(12), 2001-2006.

Lee DH, Palermo B, Chowdhury M. 2008. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clinical infectious diseases 47(4), 588-590.

LinYT, Su CF, Chuang C, Lin JC, Lu, PL, Huang CT, Fung CP. 2018. Appropriate Treatment for Bloodstream Infections Due to Carbapenem-Resistant Klebsiella pneumoniae and Escherichia coli: A Nationwide Multicenter Study in Taiwan. Open Forum Infectious Diseases 6(2).

Lodise Jr, TP, Nau R, Kinzig M, Jones R. N, Drusano G, Sörgel F. 2007. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease 58(4), 445-452.

Lutsar I, Friedland IR, Wubbel L, McCoig CC, Jafri HS, Ng W, McCracken Jr GH. 1998. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrobial agents and chemotherapy 42(10), 2650-2655.

Mace SE. 2008. Acute bacterial meningitis. Emergency medicine clinics of North America 26(2), 281-317.

MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. 2015. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. Morbidity and Mortality Weekly Report 64(41), 1171-1176.

McGill F, Heyderman R, Michael B, Defres S, Beeching N, Borrow R, Kaczmarski E. 2016. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. Journal of Infection 72(4), 405-438.

McIntyre PB, O’Brien KL, Greenwood B, Van De Beek D. 2012. Effect of vaccines on bacterial meningitis worldwide. The lancet 380(9854), 1703-1711.

Mengistu M, Asrat D, Woldeamanuel Y, Mengistu G. 2011. Bacterial and fungal meningitis and antimicrobial susceptibility pattern in Tikur Anbessa University Hospital, Addis Ababa, Ethiopia. Ethiopian medical journal 49(4), 349-359.

Meningococcal A. 2015. WHO position paper on Meningococcal A conjugate vaccine: updated guidance, February 2015.

Miller E, Andrews NJ, Waight PA, Slack MP, George RC. 2011. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. The Lancet infectious diseases 11(10), 760-768.

Miranda J, Tunkel AR. 2009. Strategies and new developments in the management of bacterial meningitis. Infectious Disease Clinics 23(4), 925-943.

Moberley S, Holden J, Tatham DP, Andrews, RM. 2013. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews (1).

Moissenet D, Salauze B, Clermont O, Bingen E, Arlet G, Denamur E, Vu-Thien H. 2010. Meningitis Caused by <i>Escherichia coli</i> Producing TEM-52 Extended-Spectrum and#x3b2;-Lactamase within an Extensive Outbreak in a Neonatal Ward: Epidemiological Investigation and Characterization of the Strain. Journal of clinical microbiology 48(7), 2459-2463.

Nadel S. 2016. Treatment of Meningococcal Disease. J Adolesc Health, 59(2 Suppl), S21-28.

Nalda-Molina R, Dokoumetzidis A, Charkoftaki G, Dimaraki E, Margetis K, Archontaki H, Vryonis E. 2012. Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. Journal of Antimicrobial Chemotherapy 67(7), 1722-1729.

Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty J, Guerin P. 2005. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. The Lancet 366(9482), 308-313.

Nau R, Sorgel F, Eiffert H. 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clinical microbiology reviews 23(4), 858-883.

Nau R, Sorgel F, Eiffert H. 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clinical microbiology reviews 23(4), 858-883.

Ntziora F, Falagas ME. 2007. Linezolid for the treatment of patients with central nervous system infection. Annals of Pharmacotherapy 41(2), 296-308.

O’Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, Hackell J. (2003). Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. The lancet 362(9381), 355-361.

Oligbu G, Collins S, Djennad A, Sheppard CL, Fry NK, Andrews NJ, Ladhani SN. 2019. Effect of pneumococcal conjugate vaccines on pneumococcal meningitis, England and Wales, July 1, 2000–June 30, 2016. Emerging infectious diseases 25(9), 1708.

Østergaard C, Klitmøller Sørensen T, Dahl Knudsen J, Frimodt-Møller N. 1998. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillinresistant pneumococcus in rabbits. Antimicrobial agents and chemotherapy 42(7), 1706-1712.

Park-Wyllie LY, Juurlink DN, Kopp A, Shah B. R, Stukel TA, Stumpo C,  Mamdani MM. 2006. Outpatient gatifloxacin therapy and dysglycemia in older adults. New England Journal of Medicine, 354(13), 1352-1361.

Patel M, Lee CK. 2005. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database of Systematic Reviews (1).

Peltola H. 2000. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clinical microbiology reviews 13(2), 302-317.

Peltola H, Anttila M, Renkonen OV, Group FS. 1989. Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. The Lancet 333(8650), 1281-1287.

Phang SY, Whitehouse K, Lee L, Khalil H, McArdle P, Whitfield PC. 2016. Management of CSF leak in base of skull fractures in adults. British journal of neurosurgery 30(6), 596-604.

Plotkin S, Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. 2009. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clinical Infectious Diseases 49(4), 597-605.

Plotkin S, Orenstein W, Offit P. 2008. Vaccines, 5th edn Philadelphia. PA: Saunders.[Google Scholar].

Podschun R, Ullmann U. 1998. <i>Klebsiella</i> spp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity Factors. Clinical microbiology reviews 11(4), 589-603.

Rafailidis PI, Falagas ME. 2014. Options for treating carbapenem-resistant Enterobacteriaceae. Current Opinion in Infectious Diseases 27(6), 479-483.

Rashid H, Ridda I, King C, Begun M, Tekin H, Wood JG, Booy R. 2015. Evidence compendium and advice on social distancing and other related measures for response to an influenza pandemic. Paediatric respiratory reviews 16(2), 119-126.

Ray L, Levasseur K, Nicolau DP, Scheetz MH. 2010. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Annals of Pharmacotherapy 44(3), 582-586.

Rostamian M, Lorestani RC, Jafari S, Mansouri R, Rezaeian S, Ghadiri K, Akya A. (2022). A systematic review and meta-analysis on the antibiotic resistance of Neisseria meningitidis in the last 20 years in the world. Indian Journal of Medical Microbiology.

Sáez-Llorens X, McCoig C, Feris JM, VargasS. L, Klugman KP, Hussey GD, Bradley J. 2002. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. The Pediatric infectious disease journal 21(1), 14-22.

Sandulescu O. 2016. Global distribution of antimicrobial resistance in E. coli. Journal of Contemporary Clinical Practice 2, 69+.

Sankar MJ, Sinha B, Chowdhury R, Bhandari, N, Taneja S, Martines J, Bahl R. 2015. Optimal breastfeeding practices and infant and child mortality: a systematic review and meta‐analysis. Acta Paediatrica 104, 3-13.

Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, Newcomer W. 1991. The Efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. New England Journal of Medicine 324(25), 1767-1772.

Scarborough M, Thwaites GE. 2008. The diagnosis and management of acute bacterial meningitis in resource-poor settings. The Lancet Neurology 7(7), 637-648.

Schaad UB, Suter S, Gianella-Borradori A, Pfenninger J, Auckenthaler R, Bernath O, Wedgwood J. 1990. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. New England Journal of Medicine 322(3), 141-147.

Sherry N, Howden B. 2018. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam – epidemiology, laboratory detection and treatment implications. Expert review of anti-infective therapy, 16(4), 289-306.

Smith SM, Sonego S, Wallen GR, Waterer G, Cheng AC, Thompson P. 2015. Use of non‐pharmaceutical interventions to reduce the transmission of influenza in adults: A systematic review. Respirology 20(6), 896-903.

Stapleton PJ, Murphy M, McCallion N, Brennan M, Cunney R, Drew RJ. 2016. Outbreaks of extended spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units: a systematic review. Archives of Disease in Childhood – Fetal and Neonatal Edition 101(1), 72-78.

Stephens DS, Greenwood B, Brandtzaeg P. (2007). Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. The Lancet 369(9580), 2196-2210.

Stephens DS, Greenwood B, Brandtzaeg P. 2007. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. The lancet 369(9580), 2196-2210.

Sugden R, Kelly R, Davies S. 2016. Combatting antimicrobial resistance globally. Nature Microbiology 1(10), 16187.

Swann O, Everett DB, Furyk JS, Harrison E M, Msukwa MT, Heyderman RS, Molyneux EM. 2014. Bacterial meningitis in Malawian infants <2 months of age: etiology and susceptibility to World Health Organization first-line antibiotics. The Pediatric infectious disease journal 33(6), 560-565.

Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Bennett NM. (2011). Bacterial meningitis in the United States, 1998–2007. New England Journal of Medicine, 364(21), 2016-2025.

Tristram S, Jacobs MR, Appelbaum PC. (2007). Antimicrobial Resistance in <i>Haemophilus influenzae</i>. Clinical microbiology reviews 20(2), 368-389.

Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ. 2004. Practice guidelines for the management of bacterial meningitis. Clinical infectious diseases 39(9), 1267-1284.

Van de Beek D, Brouwer MC, Koedel U, Wall, EC. 2021. Community-acquired bacterial meningitis. The Lancet 398(10306), 1171-1183.

Van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. 2012. Advances in treatment of bacterial meningitis. The Lancet 380(9854), 1693-1702.

Van de Beek D, Brouwer M, Hasbun R, Koedel U, Whitney CG, Wijdicks E. 2016. Community-acquired bacterial meningitis. Nature reviews Disease primers 2(1), 16074.

Van de Beek D, De Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. 2004. Clinical features and prognostic factors in adults with bacterial meningitis. New England Journal of Medicine 351(18), 1849-1859.

Van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. 2006. Community-acquired bacterial meningitis in adults. New England Journal of Medicine 354(1), 44-53.

Vergison A. 2008. Microbiology of otitis media: a moving target. Vaccine 26, G5-G10.

Wang B, Dai WJ, Cheng XT, Liuyang WY, Yuan YS, Dai CF, Chen B. 2019. Cerebrospinal fluid otorrhea secondary to congenital inner ear dysplasia: diagnosis and management of 18 cases. Journal of Zhejiang University-SCIENCE B, 20(2), 156-163.

Wang H, Kuo M, Huang S. 2005. Diagnostic approach to recurrent bacterial meningitis in children. Chang Gung Medical Journal 28(7), 441.

Ward J, Brenneman G, Letson G, Heyward W, Group AHIVS. 1990. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. New England Journal of Medicine 323(20), 1393-1401.

Wenger J, Pierce R, Deaver K, Broome C, Plikaytis B, Facklam R, Group, HIVES. 1991. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. The lancet, 338(8764), 395-398.

World Health Organization. 2015. Global action plan on antimicrobial resistance. WHO, Geneva, Switzerland.

Wu HM, Harcourt BH, Hatcher CP, Wei SC, Novak RT, Wang X, Rainbow J. 2009. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. New England Journal of Medicine 360(9), 886-892.

Yezli S, Gautret P, Assiri AM, Gessner BD, Alotaibi B. 2018. Prevention of meningococcal disease at mass gatherings: lessons from the Hajj and Umrah. Vaccine 36(31), 4603-4609.

Yogev R, Damle B, Levy G, Nachman S. 2010. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. The Pediatric infectious disease journal 29(9), 827-830.

Yusuf HR, Rochat RW, Baughman WS., Gargiullo PM, Perkins BA, Bran tley MD, Stephens DS. 1999. Maternal cigarette smoking and invasive meningococcal disease: a cohort study among young children in metropolitan Atlanta, 1989-1996. American journal of public health 89(5), 712-717.

Zouheir Y, Atany T, Boudebouch N. 2019. Emergence and spread of resistant N. meningitidis implicated in invasive meningococcal diseases during the past decade (2008–2017). J Antibiot (Tokyo), 72(3), 185-188.